Abstract
Colorectal cancer is a leading cause of death by cancer in the western world. Present oncological treatments have relatively little impact on long term survival and hope is pinned on screening. Current population-based screening methods are insufficient in reducing colorectal cancer deaths, therefore new approaches are needed. One approach is chemoprevention, which targets specific signalling pathways to interfere in the process of carcinogenesis. However, it is of great importance to critically assess the benefits of chemoprevention in comparison to its risk and inconvenience. It is unlikely that chemoprevention can be used in a wide unselected population, but is more favourable in high risk groups such as individuals especially susceptible to neoplasia because of environmental risk factors, patients with inflammatory bowel disease, those with a hereditary predisposition to CRC (FAP, Lynch, HNPCC) and patients with a previous history of colorectal cancer or adenomatous polyps. CRC is not one disease but a heterogeneous group of diseases with different underlying molecular mechanisms. Both prevention and therapy needs to be tailored to the molecular subtype of the cancer in question. This review summarises the evidence for the chemopreventive efficacy of the major agents investigated to date and their proposed molecular mechanism(s) of action.
Keywords: Chemoprevention, colorectal cancer, molecular mechanisms
Current Cancer Therapy Reviews
Title: Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Volume: 6 Issue: 2
Author(s): Rutger J. Jacobs, Liudmila L. Kodach and James C.H. Hardwick
Affiliation:
Keywords: Chemoprevention, colorectal cancer, molecular mechanisms
Abstract: Colorectal cancer is a leading cause of death by cancer in the western world. Present oncological treatments have relatively little impact on long term survival and hope is pinned on screening. Current population-based screening methods are insufficient in reducing colorectal cancer deaths, therefore new approaches are needed. One approach is chemoprevention, which targets specific signalling pathways to interfere in the process of carcinogenesis. However, it is of great importance to critically assess the benefits of chemoprevention in comparison to its risk and inconvenience. It is unlikely that chemoprevention can be used in a wide unselected population, but is more favourable in high risk groups such as individuals especially susceptible to neoplasia because of environmental risk factors, patients with inflammatory bowel disease, those with a hereditary predisposition to CRC (FAP, Lynch, HNPCC) and patients with a previous history of colorectal cancer or adenomatous polyps. CRC is not one disease but a heterogeneous group of diseases with different underlying molecular mechanisms. Both prevention and therapy needs to be tailored to the molecular subtype of the cancer in question. This review summarises the evidence for the chemopreventive efficacy of the major agents investigated to date and their proposed molecular mechanism(s) of action.
Export Options
About this article
Cite this article as:
J. Jacobs Rutger, L. Kodach Liudmila and C.H. Hardwick James, Chemoprevention of Colorectal Cancer: Progress or Pipedream?, Current Cancer Therapy Reviews 2010; 6 (2) . https://dx.doi.org/10.2174/157339410791202510
DOI https://dx.doi.org/10.2174/157339410791202510 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry The Epigenetic Origin of Aneuploidy
Current Genomics Angiogenesis Imaging Using 68Ga-RGD PET: Preliminary Report from Seoul National University Hospital
Current Medical Imaging QSAR and Docking Studies on Piperidyl-cyclohexylurea Derivatives for Prediction of Selective and Potent Inhibitor of Matriptase
Current Computer-Aided Drug Design Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance
Current Enzyme Inhibition MicroRNA-31 Inhibits Lung Adenocarcinoma Stem-Like Cells via Down-Regulation of MET-PI3K-Akt Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Drug Targets RNAi Screening for the Discovery of Novel Modulators of Human Disease
Current Pharmaceutical Biotechnology Decreased Serum Adiponectin Level Affected Clinical Pathological Characteristics of Patients with Gastric Cancer
Current Proteomics Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets Mesenchymal Stem Cells, Immune Cells and Tumor Cells Crosstalk: A Sinister Triangle in the Tumor Microenvironment
Current Stem Cell Research & Therapy Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Potential Anticancer Agents. I. Synthesis of Isoxazole Moiety Containing Quinazoline Derivatives and Preliminarily in vitro Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Nanoparticulate Drug Delivery to Colorectal Cancer: Formulation Strategies and Surface Engineering
Current Pharmaceutical Design Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study
Anti-Cancer Agents in Medicinal Chemistry Targeting Trail Towards the Clinic
Current Drug Targets Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Modulation of the Human Gut Microflora Towards Improved Health Using Prebiotics - Assessment of Efficacy
Current Pharmaceutical Design